CD39 transforming cancer therapy by modulating tumor microenvironment

被引：5

作者：

Xu, Suling ^{[1
]}

Ma, Yuhan ^{[1
]}

Jiang, Xinyu ^{[1
]}

Wang, Qingqing ^{[2
]}

Ma, Wenxue ^{[3
,4
]}

机构：

[1] Ningbo Univ, Affiliated Hosp 1, Dept Dermatol, Sch Med, Ningbo 315020, Zhejiang, Peoples R China

[2] Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China

[3] Univ Calif San Diego, Sanford Stem Cell Inst, Dept Med, La Jolla, CA 92093 USA

[4] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

来源：

CANCER LETTERS | 2024年 / 597卷

关键词：

CD39; Tumor Microenvironment (TME); Immunoregulation; Angiogenesis; Metabolic reprogramming; Therapeutic targets; EXPRESSION; PROGNOSIS; SURFACE;

D O I：

10.1016/j.canlet.2024.217072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CD39 is a pivotal enzyme in cancer, regulating immune response and tumor progression via extracellular ATP and adenosine in the tumor microenvironment (TME). Beyond its established immunoregulatory function, CD39 influences cancer cell angiogenesis and metabolism, opening new frontiers for therapeutic interventions. Current research faces gaps in understanding CD39's full impact across cancer types, with ongoing debates about its potential beyond modulating immune evasion. This review distills CD39's multifaceted roles, examining its dual actions and implications for cancer prognosis and treatment. We analyze the latest therapeutic strategies, highlighting the need for an integrated approach that combines molecular insights with TME dynamics to innovate cancer care. This synthesis underscores CD39's integral role, charting a course for precision oncology that seeks to unravel controversies and harness CD39's therapeutic promise for improved cancer outcomes.

引用

页数：11

共 110 条

[41] Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment [J].

Laubach, Kyra ;

Turan, Tolga ;

Mathew, Rebecca ;

Wilsbacher, Julie ;

Engelhardt, John ;

Samayoa, Josue .

CANCER DRUG RESISTANCE, 2023, 6 (03) :611-641

[42] Application of Artificial Intelligence to In Vitro Tumor Modeling and Characterization of the Tumor Microenvironment [J].

Lee, Ren Yuan ;

Wu, Yang ;

Goh, Denise ;

Tan, Verlyn ;

Ng, Chan Way ;

Lim, Jeffrey Chun Tatt ;

Lau, Mai Chan ;

Yeong, Joe Poh Sheng .

ADVANCED HEALTHCARE MATERIALS, 2023, 12 (14)

[43] CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker [J].

Li, Cuicui ;

Zhang, Litian ;

Jin, Qiqi ;

Jiang, Haoyun ;

Wu, Chongyang .

BIOMARKERS IN MEDICINE, 2023, 17 (12) :563-576

[44] Signaling pathways in brain tumors and therapeutic interventions [J].

Li, Shenglan ;

Wang, Can ;

Chen, Jinyi ;

Lan, Yanjie ;

Zhang, Weichunbai ;

Kang, Zhuang ;

Zheng, Yi ;

Zhang, Rong ;

Yu, Jianyu ;

Li, Wenbin .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)

[45] Immunophenotyping with high-dimensional flow cytometry identifies Treg cell subsets associated with recurrence in papillary thyroid carcinoma [J].

Li, Sijin ;

Chen, Zhen ;

Liu, Mengchu ;

Li, Liang ;

Cai, Wensong ;

Lian, Zhe-Xiong ;

Guan, Haixia ;

Xu, Bo .

ENDOCRINE-RELATED CANCER, 2024, 31 (03)

[46] Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity [J].

Li, Xian-Yang ;

Moesta, Achim K. ;

Xiao, Christos ;

Nakamura, Kyohei ;

Casey, Mika ;

Zhang, Haiyan ;

Madore, Jason ;

Lepletier, Ailin ;

Aguilera, Amelia Roman ;

Sundarrajan, Ashmitha ;

Jacoberger-Foissac, Celia ;

Wong, Clifford ;

dela Cruz, Tracy ;

Welch, Megan ;

Lerner, Alana G. ;

Spatola, Bradley N. ;

Soros, Vanessa B. ;

Corbin, John ;

Anderson, Ana C. ;

Effern, Maike ;

Hoelzel, Michael ;

Robson, Simon C. ;

Johnston, Rebecca L. ;

Waddell, Nicola ;

Smith, Corey ;

Bald, Tobias ;

Geetha, Nishamol ;

Beers, Courtney ;

Teng, Michele W. L. ;

Smyth, Mark J. .

CANCER DISCOVERY, 2019, 9 (12) :1754-1773

[47] Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data [J].

Lippenszky, Levente ;

Mittendorf, Kathleen F. ;

Kiss, Zoltan ;

LeNoue-Newton, Michele L. ;

Napan-Molina, Pablo ;

Rahman, Protiva ;

Ye, Cheng ;

Laczi, Balazs ;

Csernai, Eszter ;

Jain, Neha M. ;

Holt, Marilyn E. ;

Maxwell, Christina N. ;

Ball, Madeleine ;

Ma, Yufang ;

Mitchell, Margaret B. ;

Johnson, Douglas B. ;

Smith, David S. ;

Park, Ben H. ;

Micheel, Christine M. ;

Fabbri, Daniel ;

Wolber, Jan ;

Osterman, Travis J. .

JCO CLINICAL CANCER INFORMATICS, 2024, 8

[48] Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients [J].

Liu, Chunnan ;

Liu, Zhaopei ;

Jin, Kaifeng ;

Zeng, Han ;

Shao, Fei ;

Chang, Yuan ;

Wang, Yiwei ;

Xu, Le ;

Wang, Zewei ;

Zhu, Yu ;

Zhang, Weijuan .

BRITISH JOURNAL OF CANCER, 2022, 127 (09) :1718-1725

[49] Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment [J].

Liu, Lilong ;

Hou, Yaxin ;

Deng, Changqi ;

Tao, Zhen ;

Chen, Zhaohui ;

Hu, Junyi ;

Chen, Ke .

NATURE COMMUNICATIONS, 2022, 13 (01)

[50]

Liu M., 2023, Cancers, V15

← 1 2 3 4 5 6 7 8 9 10 →